Calculate the CHA2DS2-VASc score line by line in patients with atrial fibrillation (AF), then compare the total with the 2023 ACC/AHA/ACCP/HRS thresholds (sex-specific) or the 2024 ESC thresholds (sex-neutral). The two guidelines disagree on the female sex point.
How do you calculate the CHA2DS2-VASc score?
Give 2 points each for age 75 or older and for prior stroke, TIA or thromboembolism. Give 1 point each for heart failure, hypertension, diabetes, vascular disease, age 65 to 74, and female sex.
The 2023 ACC/AHA/ACCP/HRS guideline lists these components. The 2024 ESC guideline defines the same items for CHA2DS2-VA without the sex line.
| Component | Points | Notes |
|---|---|---|
| Heart failure | 1 | ESC counts symptoms regardless of LVEF, or asymptomatic LVEF 40% or lower |
| Hypertension | 1 | ESC: resting BP above 140/90 mmHg on two occasions, or current treatment |
| Age 75 or older | 2 | Replaces the 65 to 74 point |
| Diabetes mellitus | 1 | ESC includes anyone on glucose-lowering therapy |
| Prior stroke, TIA or arterial thromboembolism | 2 | |
| Vascular disease | 1 | ESC: coronary disease including prior MI, or peripheral vascular disease |
| Age 65 to 74 | 1 | Applies only below 75 |
| Female sex | 1 | Scored in CHA2DS2-VASc, dropped in CHA2DS2-VA |
Run the arithmetic with the CHA2DS2-VASc calculator. The older CHADS2 score omits vascular disease, age 65 to 74 and sex. In the 2010 derivation paper, CHA2DS2-VASc placed fewer patients in the intermediate group (15.1%) than CHADS2 (61.9%).
What score warrants anticoagulation under current guidelines?
Anticoagulate at an estimated annual thromboembolic risk of 2% or more under the 2023 US guideline, or at a CHA2DS2-VA of 2 or more under the 2024 ESC guideline. Both guidelines treat the next band down as a shared decision.
- US 2023: Class 1, Level A at 2% or more per year (for example, 2 or higher in men, 3 or higher in women). Class 2a, Level A ("reasonable") at 1% to under 2%, equivalent to 1 in men and 2 in women.
- DOAC over warfarin in eligible patients, meaning those without moderate to severe rheumatic mitral stenosis or a mechanical heart valve.
- ESC 2024: recommended at 2 or more and considered at 1, using a patient-centred, shared approach. An ACC summary lists the same thresholds.
Why did the ESC drop the sex category?
The ESC task force calls female sex an age-dependent stroke risk modifier and proposes CHA2DS2-VA in the absence of locally validated alternatives. The US guideline keeps CHA2DS2-VASc, shifts women's thresholds up one point, and names female sex among the risk modifiers that future scores may incorporate better.
Most patients get the same answer from either guideline. A woman with a CHA2DS2-VASc of 3 has a CHA2DS2-VA of 2, and a man scoring 2 gets the same result under both. The frameworks diverge at the borderline: a woman with a CHA2DS2-VASc of 2 gets Class 2a "reasonable" under the US guideline, while her CHA2DS2-VA of 1 prompts "should be considered" under the ESC.
A retrospective cohort of 3,370 adults aged 65 to 90 with new-onset AF found that CHA2DS2-VA removed the sex gap in risk strata. Its authors state this does not show better prediction.
Which scoring mistakes come up most often?
Check age, sex and the three loosely defined conditions before you total the score. Each error can shift a patient across a threshold.
- Age bands. Age 65 to 74 earns 1 point and 75 or older earns 2. Age 78 scores 2.
- Female sex alone. A woman whose only point is sex scores 1, which sits below the US intermediate band (2 in women).
- Hypertension. The ESC definition includes current treatment, so a well-controlled patient on antihypertensives still scores.
- Heart failure. The ESC definition covers symptoms regardless of LVEF, so preserved ejection fraction counts.
- Vascular disease. ESC lists coronary disease including prior MI, and peripheral vascular disease. The 2023 US guideline names the category only, so check your calculator's definition.
Where does this fall short?
The Lip 2010 abstract reports a C-statistic of 0.606, only marginally better than CHADS2. The 2023 US guideline notes that the score performs suboptimally in selected populations such as renal disease, omits AF characteristics like burden, and says bleeding risk scores should not be used in isolation in patients at high stroke risk. The ESC guideline says to consider other modifiers such as cancer, chronic kidney disease, ethnicity, troponin and BNP. As of 2026-10-10, a September 2026 guideline listing shows no AF stroke-prevention guideline newer than the 2024 ESC document, and the 2026 ACC/AHA AF update covers performance and quality measures without changing risk thresholds, so confirm against your society's site before you update protocols.
Run the numbers
Quick answers
How do you calculate the CHA2DS2-VASc score?
Add 2 points each for age 75 or older and prior stroke, TIA or thromboembolism. Add 1 point each for heart failure, hypertension, diabetes, vascular disease, age 65 to 74, and female sex. The maximum is 9.
What CHA2DS2-VASc score warrants anticoagulation?
The 2023 ACC/AHA/ACCP/HRS guideline recommends anticoagulation at an estimated annual risk of 2% or more (score 2 or higher in men, 3 or higher in women). It calls anticoagulation reasonable at 1 in men or 2 in women.
What is the difference between CHA2DS2-VASc and CHA2DS2-VA?
CHA2DS2-VA, used in the 2024 ESC guideline, removes the female sex point. It uses one threshold for everyone: anticoagulation is recommended at 2 or more and should be considered at 1.
Do age 65 to 74 and age 75 or older both score?
No. The age bands exclude each other: 65 to 74 scores 1 point and 75 or older scores 2 points.
Keep reading
Have a clinical question of your own?
Ask in plain language. CliniWiz shows its reasoning and links the sources behind every answer.
Ask CliniWiz